YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR/MAPK pathway and abrogating autophagy in non-small cell lung cancer

YAP1 is a well-known core effector of the Hippo pathway in tumors, but its potential role in osimertinib resistance remained unexplored. Our study provides evidence that YAP1 acts as a potent promoter of osimertinib resistance. By inhibiting YAP1 with a novel inhibitor, CA3, and combining it with os...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Yue, Zheng, Hongmei, Yang, Yang, Zang, Hongjing, Wang, Weiyuan, Zhan, Yuting, Wang, Haihua, Luo, Jiadi, Wen, Qiuyuan, Peng, Jinwu, Xiang, Juanjuan, Fan, Songqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197898/
https://www.ncbi.nlm.nih.gov/pubmed/37215986
http://dx.doi.org/10.7150/ijbs.79965

Ejemplares similares

Ejemplares similares